Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly reports positive growth in third quarter of 2013

Lilly reports positive growth in third quarter of 2013

28th October 2013

Lilly has announced its financial results for the third quarter of 2013, reporting a three-month revenue total of $5.77 billion (3.56 billion pounds).

This represented a six percent year-on-year increase, thanks to strong growth for products such as Cymbalta, Alimta, Cialis, Trajenta and its insulin range, while its animal health division also made a significant contribution.

The success of these products will be encouraging to Lilly as it continues to recover from the impact of a recent string of patent expiries for some of its largest products, while the completion of four regulatory filings this year will strengthen its future pipeline further.

Lilly expects its 2013 revenue total to be somewhere between $22.6 billion and $23.4 billion.

Dr John Lechleiter, Lilly's chairman, president and chief executive officer, said: "We are successfully executing our strategy which will enable us to return to growth after 2014 by bringing to the market new medicines that make a real difference for patients."

This comes after the firm announced the appointment of Jackson Tai to its board of directors earlier this month.ADNFCR-8000103-ID-801653962-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.